

Disclosures

Personal Commercial (7)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Acute Coronary Syndromes Stable Ischemic Heart Disease</i>
Acist Medical	Consultant Fees/Honoraria	Modest (< \$5,000)	<i>Stable Ischemic Heart Disease</i>
AstraZeneca Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	<i>Acute Coronary Syndromes</i>
Auxilius Pharma	Other - <i>Consultant</i>	None (\$0)	<i>Stable Ischemic Heart Disease</i>
GSK	Research/Research Grants ‡ <i>SoftMech</i>	Significant (>= \$5,000)	<i>Noninvasive Imaging</i>
HeartFlow	Consultant Fees/Honoraria	Significant (>= \$5,000)	<i>Noninvasive Imaging</i>
Novartis Corporation	Research/Research Grants ‡ <i>Study of the Vascular Effects of Serelaxin; NCT01979614</i>	Significant (>= \$5,000)	<i>General Cardiology</i>

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (9)

Trial Name	Trial Sponsor	Trial Funding Source
Global Leaders; NCT01813435	Biosensors International	Biosensors
Leaders Free; NCT01623180	Biosensors International	Biosensors International
EVOLVE	Boston Scientific International S.A.	
Edify Heart Failure with Preserved Ejection Fraction – CL2-16257-101	InspireMD	
MASTER II Trial (V6.0)	INSPIRE-MD	
AMICI; NCT01781390	Mesoblast, Ltd.	Mesoblast, Ltd.
CATCH-AMI; NCT01905475	Polyphor Ltd.	Polyphor Ltd.
FAME-3; NCT02100722	Stanford University	St Jude Medical; Medtronic
RIPCORDER-2	University of Southampton	BostonScientific

Institutional Financial Decision-Making Role (1)

Funding Source	Institutional Compensation Level
Abbott Laboratories	Significant (>= \$5,000)

Expert Witness Testimony (0)

No disclosures on record

‡ *Commercial Funding Source* | ‡ *Trial Name*

Agreement

Certified Education Attestation | Signed on 12/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 12/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 12/3/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 12/3/2023

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.